Equities researchers at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock. Shares of NAVB stock opened at $0.69 on Friday. The firm has a 50 day moving average of $0.81. Navidea […]
Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) and Heska (NASDAQ:HSKA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Institutional and Insider Ownership 5.6% of Navidea Biopharmaceuticals shares are […]
Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) and VolitionRx (NYSE:VNRX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings. Profitability This table compares Navidea Biopharmaceuticals and VolitionRx’s net margins, […]
Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) and StageZero Life Sciences (OTCMKTS:SZLSF – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation. Risk & Volatility Navidea Biopharmaceuticals has a beta […]
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) and Navidea Biopharmaceuticals (NYSE:NAVB – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership. Analyst Recommendations This is a summary of current […]